Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Polyvalent Antivenom (Premium-PANAF) for Snakebite Envenoming in Ethiopia

15. juni 2026 opdateret af: Medecins Sans Frontieres, Netherlands

A Prospective Cohort Study of Polyvalent Antivenom (Premium-PANAF) for Snakebite Envenoming in Ethiopia

Snakebite Envenomation is recognised as a Neglected Tropical Diseases with high lethality in Sub-Saharan Africa. The current syndromic treatment approach is also fraught by supply pipeline constraints and need for cold-chain, thus negatively impacting outcomes in resource limited settings.

Despite the lack of clinical outcome data from studies in humans, after a comprehensive risk-benefit assessment, the World Health Organisation (WHO), in May 2023, recommended the use of Premium-PANAF polyvalent snake antivenom that is lyophilised, and therefore does not require cold-chain conditions. Médecins Sans Frontières (MSF) also updated its treatment protocol with Premium PANAF being standard of care since June 2025 at Abdurafi (Midre Genet) Health Centre in north west Ethiopia.

Real-world effectiveness by means of Phase IV post marketing studies or pharmacovigilance programmes in countries where it has recently been rolled out is not yet available. This prospective observational cohort study, with a capped sample size of 600 patients, would thus provide much needed evidence on the safety and effectiveness of Premium-PANAF in resource limited settings to help inform national and international treatment guidelines.

Studieoversigt

Status

Rekruttering

Betingelser

Undersøgelsestype

Observationel

Tilmelding (Anslået)

600

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Etiopien
    • Amhara
      • Ābderafī, Amhara, Etiopien
        • Rekruttering
        • Abdurafi Health Center
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Barn
  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Patients presenting to Abdurafi health centre in Northwest Ethiopia with snakebite envenoming from June 2025 - June 2026.

Beskrivelse

Inclusion criteria

  • Snakebite envenoming patients who receive Premium-PANAF antivenom
  • Patients who have given written informed consent .

Exclusion criteria

  • Snakebite envenoming patients who do not receive Premium-PANAF antivenom
  • Patients referred from other centres who already received other antivenom treatment
  • Patients who are unable or unwilling to give informed consent

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Kohorter og interventioner

Gruppe / kohorte
Snakebite Envenomation treated with Premium PANAF
Patients admitted with snakebite envenomation who recieve Premium PANAF antivenom as standard of care and consent for particpation in the study

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Safety (Allergic Reactions)
Tidsramme: 6 hours
Proportion of patients with severe allergic reactions within 6 hours of antivenom administration according to the Brown grading system
6 hours
Effectiveness (Correction of Coagulopathy)
Tidsramme: 6 hours
Correction of coagulopathy as measured by the 20-minute whole blood clotting test at 6 hours after antivenom administration
6 hours

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Effectiveness (Number of Vials)
Tidsramme: 14 days
Number of doses (vials) needed to reverse the envenomation syndrome
14 days
Effectiveness (Rescue Treatment)
Tidsramme: 14 days
Proportion of patients who require rescue treatment with EchiTab-Plus or SAIMR due to lack of responsiveness to Premium-PANAF
14 days
Effectiveness (Mortality)
Tidsramme: 42 days
Death from any cause within 42 days of treatment with antivenom
42 days
Effectiveness (Patient Specific Function Scale)
Tidsramme: 42 days
Patient-specific Function Scale (PSFS) score
42 days
Effectiveness (Major Bleeding)
Tidsramme: 7 days
Proportion of patients with in-hospital major bleeding (defined according to the International Society on Thrombosis and Haemostasis criteria)
7 days
Effectiveness (Cessation of Bleeding)
Tidsramme: 6 hours
Proportion of patients with cessation of bleeding
6 hours
Effectiveness (Serial 20WBCT)
Tidsramme: 14 days
Proportion of patients with reversal of correction of coagulopathy as measured by serial 20min WBCT
14 days
Effectiveness (Blood Transfusion)
Tidsramme: 14 days
Proportion of patients who require blood transfusion during hospitalization
14 days
Effectiveness (Surgical Intervention)
Tidsramme: 14 days
Proportion of patients who require surgical intervention
14 days
Effectiveness (Skin Necrosis)
Tidsramme: 48 hours
Mean and median total surface area of full thickness skin necrosis in cm2
48 hours
Effectiveness (Swelling Reduction)
Tidsramme: 6 hours
Reduction of swelling extension
6 hours
Effectiveness (Renal Replacement Therapy)
Tidsramme: 14 days
Proportion of participants referred for renal replacement therapy
14 days
Effectiveness (Creatine Kinase)
Tidsramme: 14 days
Peak serum creatine kinase in U/L
14 days
Effectiveness (Need for Ventilation)
Tidsramme: 48 hours
Proportion of participants needing mechanical or manual ventilation
48 hours
Safety (Presence of Shock)
Tidsramme: 3 hours
Proportion of patients with shock (shock defined as systolic blood pressure <90mmHg in adults, or age adjusted blood pressure in children)
3 hours
Safety (Need for Adrenaline)
Tidsramme: 14 days
Proportion of patients requiring adrenaline
14 days
Safety (Anaphylaxis)
Tidsramme: 2 hours
Proportion of patients experiencing anaphylaxis after antivenom administration
2 hours
Safety (Need for intravenous fluids)
Tidsramme: 2 hours
Proportion of patients requiring IV fluids following an allergic reaction
2 hours
Safey (Serum Sickness)
Tidsramme: 28 days
Proportion of patients with confirmed or probable serum sickness
28 days
Safety (Any Other)
Tidsramme: 7 days
Any other (serious) adverse events after enrolment in the study among participants with at least one dose of antivenom delivered
7 days

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Medecins Sans Frontieres, Netherlands

Samarbejdspartnere

University of Gondar, Gondar, Ethiopia

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

2. juni 2025

Primær færdiggørelse (Anslået)

1. august 2026

Studieafslutning (Anslået)

1. september 2026

Datoer for studieregistrering

Først indsendt

21. maj 2026

Først indsendt, der opfyldte QC-kriterier

15. juni 2026

Først opslået (Faktiske)

22. juni 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

22. juni 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

15. juni 2026

Sidst verificeret

1. juni 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • ID2452-Remit-OCA024-07

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

All of the individual participant data collected during the study, after de-identification.

IPD-delingstidsramme

Beginning 3 months and ending 5 years following article publication.

IPD-delingsadgangskriterier

Anyone who wishes to access the data in line with MSF data sharing policy: https://www.msf.org/sites/default/files/msf_data_sharing_policy_final_061213.pdf

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • ICF

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Slangeforgiftning

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Lithuania

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner